Status: Recruiting
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
Participants needed: 10
Trial details
Phase: Early Phase 1Age: 45-75Biological sex: AllType: InterventionalSponsor: Austin Neuromuscular CenterUpdated: Jan 16, 2026Locations: 2
Eligibility criteria
1. Age ≥45 years to 75 years of age 2. Diagnosed with sIBM based on the ENMC IBM... [+7]
1. Other neurological conditions (e.g., hemiplegia post-stroke, Parkinson's Dise...